Tariquidar

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTariquidar
Drug Alias NameTariquidarum他利奎达他立喹达XR-9576
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP-glycoprotein 1 inhibitors
TargetsP-glycoprotein 1
Therapy Area/IndicationsNeuralgiaCarcinoma, Non-Small-Cell LungBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXenova
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of Medicine
Inactive CompaniesQlt IncXenovaNovelion Therapeutics Inc +[4] 
Active IndicationsNeuralgia
Inactive IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG